A study to evaluate the Efficacy and Safety of AZD8931 in Combination with Anastrozole, compared to Anastrozole alone in Post-menopausal Women With Locally-advanced or Metastatic Breast Cancer.
Phase 2
Completed
- Conditions
- Health Condition 1: null- Locally advanced or Metastatic Breast CancerHealth Condition 2: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2010/091/002961
- Lead Sponsor
- AstraZeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 23
Inclusion Criteria
Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent
- Hormone therapy-naive
- Estimated life expectancy of more than 12 weeks
Exclusion Criteria
- Last dose of prior anti-cancer therapy received within 14 days (or longer if required)
- Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.
- Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose <7 days prior to randomisation)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method